Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Green industry yes, conservation no: a budget for people, not for nature 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
ALWAYTH x Adidas Samba: Revolutionizing Sneaker Culture with Fashion-Forward Collaboration 
Skepta and PUMA Launch Groundbreaking Collection 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
McDonald's China Faces Backlash for Food Hygiene Violations 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Lapstone & Hammer Expands ASICS 'Dip Dye' Series with Beverage-Inspired Colorways 
SAN FRANCISCO, Oct. 10, 2016 -- Hagens Berman Sobol Shapiro LLP is continuing its investigation of possible securities law violations by Theranos, Inc. and its management.
If you are an investor in Theranos financing rounds and suspect you have lost money, contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/Theranos
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
Our initial investigation indicates that Theranos may have made significant misrepresentations about the state of the Company’s technology and operations when it solicited investments.
On October 6, 2016, the Wall Street Journal reported Theranos would shut down its blood-testing facilities and dismiss more than 40% of its employees after regulators banned Theranos CEO Elizabeth Holmes from owning or operating a lab for two years.
“We’re probing Theranos’s relationships with investors, the representations made to them, and this apparently self-interested shift in business strategy,” said Hagens Berman partner Reed Kathrein. ”Sources indicate that Theranos sold stock in a Series C round to investor in 2014 and 2015. Normally, by the time of a Series C round, the technology or product is proven and the funds are used to expand the products’ presence in the market.”
Whistleblowers: Persons with non-public information regarding Theranos should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the SEC whistleblower program, whistleblowers who provide original information may receive rewards up to 30 percent of any successful recovery made by the SEC. For more information concerning your whistleblower options, call Reed Kathrein at (510) 725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
